Tune in as we define high yield and distressed debt, discuss the current state of the market, and explore the impact of rising interest rates and inflation on highly levered companies. Listen here: https://lnkd.in/e-PJMy8j Featuring: Jane Ross and Eric Friel
Oppenheimer & Co. Inc.
Financial Services
New York, NY 60,088 followers
Oppenheimer provides a full range of wealth management, securities brokerage, and investment banking services.
About us
Oppenheimer & Co. Inc. is a leading national investment boutique with over a century of tradition. Oppenheimer’s culture of providing innovative, customized solutions to our clients sets us apart from our competitors. Oppenheimer is proud of its reputation as a Firm that helps individuals, families, corporate executives, foundations and endowments, charities, pension plans businesses, and institutions. We occupy a unique position in the industry, thanks to the dedication, expertise, and creativity of our people. Oppenheimer Financial Advisors draw on the extensive resources and expertise of nearly 1,900 other professionals, including those in Equity Research, Capital Markets, and Investment Banking. Oppenheimer Asset Management Inc., Oppenheimer Life Agency Ltd., Oppenheimer Trust Company of Delaware and Oppenheimer & Co. Inc. are wholly owned subsidiaries of Oppenheimer Holdings Inc., an integrated financial holding company. Oppenheimer is a registered broker-dealer and investment advisory firm. Securities are offered through Oppenheimer.
- Website
-
http://www.oppenheimer.com
External link for Oppenheimer & Co. Inc.
- Industry
- Financial Services
- Company size
- 1,001-5,000 employees
- Headquarters
- New York, NY
- Type
- Public Company
- Founded
- 1881
- Specialties
- Wealth Management, Debt and Equity Capital Markets, Mergers & Acquisitions, Retirement Services, Asset Management, Investment Banking, and Equity Research
Locations
Employees at Oppenheimer & Co. Inc.
Updates
-
We are thrilled to announce that we are finalists for the Fintech B2B Marketing Community Global Awards! 🎉 Our nominations for Best Integrated Multi-Channel Marketing Campaign and Best Brand Launch reflect our commitment to innovation and excellence. Thank you to our incredible team and partners for making this possible! #ThePowerofOppenheimerThinking
-
-
We are pleased to have acted as Sole Bookrunner on Vaxart, Inc.’s $40MM Registered Direct Offering
-
Today we announced the continued expansion of our Fixed Income Division with the addition of 10 more High Yield and Distressed Debt Team members. The additions coincide with a more challenging credit environment and expansion of the firm’s restructuring and debt advisory capabilities. At Oppenheimer, we are well positioned to help clients navigate ballooning inflation and elevated interest rates, which have reached a 13-year high while net interest expenses have soared to levels not seen in 30 years. #ThePowerofOppenheimerThinking
Oppenheimer Announces Additions to the High Yield and Distressed Debt Team
oppenheimer.com
-
The hotter than expected producer price report looked to us to provide the Fed an opportunity to keep to its pause mode on rates until November...
As the World Turns | 07/15/2024 Market Strategy
oppenheimer.com
-
“It’s the end of free money and we think it’s a good thing.” Oppenheimer Asset Management's Chief Investment Strategist, John Stoltzfus gives his thoughts on the current interest rate environment. Click here for his full mid-year market update: https://lnkd.in/epQ73HGV #ThePowerofOppenheimerThinking
-
We are pleased to welcome Andreas Argyrides as Executive Director and Senior Analyst covering the Biotechnology sector. Andreas has more than 15 years of financial industry experience. His expertise includes coverage of companies engaged in the development of new therapies for eye, liver, and lung diseases as well as gene therapies for rare genomic diseases.
Appoints Andreas Argyrides as Executive Director and Senior Analyst Covering the Biotechnology Sector
oppenheimer.com
-
We are pleased to have acted as Sole Dealer Manager to TriSalus Life Sciences, Inc. on its Public Warrant Exchange of 7.0 Million Warrants.
Sole Dealer Manager to TriSalus Life Sciences, Inc.
oppenheimer.com
-
Oppenheimer has appointed Rayna Kumar as Managing Director and Senior Analyst for the Fintech sector. Leading a four-person team from our New York office, Rayna brings extensive expertise in the payments ecosystem, from card networks to AI in finance. Welcome aboard, Rayna! 🚀 #Fintech #Leadership #ThePowerofOppenheimerThinking https://lnkd.in/eTzUYBXZ
Oppenheimer Appoints Rayna Kumar as Managing Director and Senior Analyst Covering the Fintech Sector
oppenheimer.com